The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register - Wikidata - wikimedia - TriplyDB

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register

http://www.wikidata.org/entity/Q36020193

about

Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.Online training on skin cancer diagnosis in rheumatologists: results from a nationwide randomized web-based survey Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link.Risk of Malignant Neoplasm in Patients with Incident Rheumatoid Arthritis 1980-2007 in relation to a Comparator Cohort: A Population-Based Study The BSRBR-RA at 15 years.The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers Infectious and malignant complications of TNF inhibitor therapy in IBD.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Safety profile of biological therapies for treating rheumatoid arthritis.Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study.Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis.Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies.Incidence of malignancies in patients with juvenile idiopathic arthritis: A retrospective single-center cohort study in Germany.Safety of tumor necrosis factor inhibitor therapy in patients with a prior malignancy.Coexistent malignant conditions in rheumatoid arthritis - A population-based cross-sectional study.[Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study.[Malignancies of the skin and immunomodulatory antirheumatic therapy].Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study.Etanercept in the treatment of rheumatoid arthritis.Unleashing endogenous TNF-alpha as a cancer immunotherapeutic

P2860

Q26822912-B4989CC3-16AE-4227-871A-4F3064492F04 Q28074148-CF2081E6-2452-424E-A183-5B7454AC3392 Q31041008-3D614B36-26ED-4C31-8252-EA9374283838 Q35633961-0E855CD1-401B-42AE-BB06-1FD0CEE6902B Q36464357-4B903C61-711B-4FB8-897D-9888EE195C34 Q37100264-430169F7-B947-45DF-9A86-B310B9FD8EDC Q37218755-4019E89C-2A86-4513-95C8-7F1A3C4FEA84 Q37333943-B403FE55-464C-4DBB-9303-F141BADD04AE Q37383424-17462B57-07AA-476B-87C4-CF84C10D85A3 Q37616987-42B44C23-6F23-4228-8433-63F7B8896328 Q38138343-D45DDBF5-06D3-41D0-B5B3-41E6283B179D Q38176745-D775E862-8EE2-40FD-9885-8A67BB05610B Q38665700-7F7AFE2B-A5D4-4DCD-AA8A-D75C9B56F421 Q38668352-5777D258-C4BF-467B-9994-6F698D775307 Q38755133-D6D8CEBF-DE35-46CF-ADA8-0D8F286B6ABC Q39137571-78C4E06A-1701-4C75-83B0-C17E5424381C Q39309064-2AF00067-5026-4F9F-9D5C-92F83E8B1222 Q39454180-97539902-2A07-4B63-A785-D7AE98569837 Q39623636-094BE8DE-10BA-4F2F-A1AF-28BF25109D4F Q39811930-7423F567-4F73-462D-9F17-D2502E3C7BE6 Q40354684-2E7ECE20-4932-4D86-A0C7-D9A4E723CF97 Q40826525-188948D2-D9E0-429B-99EF-805C2467FB00 Q40889610-416F55DB-3A84-414F-B950-C40940973086 Q40949266-BA0B8300-79C0-41BA-9805-A96E3A71BD17 Q47831413-B851CF49-3BA1-49C3-8E35-5C5C8D9CEAF3 Q49783699-24E5E44B-BCDC-40A9-B13A-050061714C91 Q51000616-C1F929CE-45D2-4ACC-B048-2AB753E99630 Q52841141-7FC9A9E8-B1DC-4509-BDAC-FA3778143522 Q58781970-545E5D85-1940-4357-BD63-190A42C0510E

P2860

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register

http://www.wikidata.org/entity/Q36020193

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The influence of anti-TNF ther ...... heumatology Biologics Register

@ast

The influence of anti-TNF ther ...... heumatology Biologics Register

@en

type

label

The influence of anti-TNF ther ...... heumatology Biologics Register

@ast

The influence of anti-TNF ther ...... heumatology Biologics Register

@en

prefLabel

The influence of anti-TNF ther ...... heumatology Biologics Register

@ast

The influence of anti-TNF ther ...... heumatology Biologics Register

@en

P1433

Q36020193-ADC0BB90-3AE1-4D26-B3B3-46A5956D76E8

P1476

Q36020193-A36A513B-8BD8-415A-A621-D16CFA643CE5

P2093

Q36020193-08A358CC-372B-41E7-9590-1BD7F20ED9E6

Q36020193-36A65261-4316-40DD-8F23-7EB59B445E9C

Q36020193-463718CE-54DA-46AB-89FA-A764F7F66768

Q36020193-57ACE7D7-971D-4763-9844-0D59F92B4008

Q36020193-8A10F73F-75E4-4D44-8703-23D339AAA6E2

Q36020193-8EEDB5C4-09FA-4CF7-8B23-26E751C84B7D

P2860

Q36020193-0471A3B2-6FE2-44A0-9C4D-D3C1A4E38E74

Q36020193-0E15C8BF-ABA9-40E8-A391-8D88E395B3E5

Q36020193-178342AC-AE7E-46E5-8CCE-54B56130BBDF

Q36020193-22E3D67E-DA5B-4CD1-A615-9CE2AAC6CE57

Q36020193-3C620C22-635B-4498-BC61-B7457DEF24A0

Q36020193-47D0217D-0FD3-4EA4-8EED-B18657BDDE1A

Q36020193-5EB3AF5F-110C-4EBB-8CC6-02E25A2B79E6

Q36020193-8950B827-3F75-442E-8597-A8F5D839FD1B

Q36020193-8A259F9D-9F9A-4A82-99FC-2707E99763ED

Q36020193-94E7F1D2-91DC-49FD-8E90-09446122885F

P304

Q36020193-A88B24DE-C35B-404E-8284-7BF62831AE0C

P31

Q36020193-68FD700C-DF7E-4707-85F2-830B3AED5D4F

P356

Q36020193-464299BA-E409-473F-9952-2787496173D4

P407

Q36020193-EED7F4C6-D244-418D-AC52-B3A3D9A987F9

P433

Q36020193-CC54CB23-7B27-4B76-8D43-E84CA07AD861

P478

Q36020193-AE7BB6DC-4633-4350-A56E-354FE56B51ED

P50

Q36020193-1060878A-5910-4667-BD24-586389967BD7

Q36020193-85A9B15B-1F4F-4D04-B2D3-014322437770

Q36020193-9113134C-119D-47A3-BCBC-E38A8B01BB43

Q36020193-E306992A-1154-4AA3-B737-7CA86BD91F38

Q36020193-EAA4E2D3-E960-422F-AB2D-28356FC7F9B9

P577

Q36020193-201FA493-EACB-4C93-B9AA-1EE8E08A761D

P5875

Q36020193-7B9AF5E1-127C-4095-9707-611EF27F91C0

P698

Q36020193-302D394F-BE4A-42A8-9445-9BE19C7EF76C

P921

Q36020193-B92FBFD5-5D64-46E2-87E9-29A33A413951

P932

Q36020193-16C88368-02EE-46B6-A384-6D12B5612A71

P356

ANNRHEUMDIS-2011-200622

P1433

Annals of the Rheumatic Diseases

P1476

The influence of anti-TNF ther ...... heumatology Biologics Register

@en

P2093

Adele C Green

http://www.w3.org/2001/XMLSchema#string

British Society for Rheumatology Biologics Register Control Centre Consortium

http://www.w3.org/2001/XMLSchema#string

British Society for Rheumatology Biologics Register

http://www.w3.org/2001/XMLSchema#string

Kath D Watson

http://www.w3.org/2001/XMLSchema#string

Kimme L Hyrich

http://www.w3.org/2001/XMLSchema#string

Louise K Mercer

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.

Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996.

How complete and accurate are cancer registrations notified by the National Health Service Central Register for England and Wales?

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

The British Society for Rheumatology biologics register.

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.

Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior.

Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis.

Rheumatoid arthritis and the risk of malignancy.

Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial.

P304

869-874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2011-200622

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Deborah P.M. Symmons

James B Galloway

P577

2012-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221744582

http://www.w3.org/2001/XMLSchema#string

P698

22241900

http://www.w3.org/2001/XMLSchema#string

P921

P932

3371225

http://www.w3.org/2001/XMLSchema#string